Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Hervé Bonnefoi et al.|The Lancet|2014Cited by 4.7k
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger, Daniel G. Stover, Katharine A. Collier et al.|npj Breast Cancer|2021Cited by 37